Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis Refractory to Biologic Therapy: 1-year Results From the Open-label Extension of a Phase III Study

The efficacy and safety of updacitinib in bDMARD-IR patients with AS were sustained through to one year in an open-label extension of the SELECT-AXIS 2 study.

Patients receiving UPA had sustained improvement in ASAS40, ASDAS LDA, ASDAS ID, total back pain, nocturnal back pain, and BASFI up to 52 weeks, regardless of whether they receive UPA or PBO in the first 14 weeks of the study.